TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
TopoTarget A/S held an extraordinary general meeting on 23 July 2009 in
accordance with the notice convening the meeting issued on 9 July 2009.
At the general meeting, the Board of Directors proposed the changes to the
Board of Directors set out below:
As the current board members Jesper Zeuthen and Torbjörn Bjerke have informed
the company that they wish to resign from the Board in connection with the
extraordinary general meeting, the Board proposes that Anders Fink Vadsholt,
Per Samuelsson and Bo Jesper Hansen be elected to the Company's Board of
Directors for the period until the Annual General Meeting to be held in 2010.
The Company thanked Jesper Zeuthen and Torbjörn Bjerke for their efforts and
commitment while serving on the Board.
Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen were unanimously
elected to the Board of Directors at the general meeting. Section 49(6) of the
Danish Public Companies Act was complied with and the shareholders were given a
presentation of Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen.
The Company's Board of Directors now consists of the following seven members:
Håkan Åström, Jeffrey H. Buchalter, Anders Gersel Pedersen, Ingelise Saunders,
Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen.
Immediately following the extraordinary general meeting, the Board of Directors
elected Håkan Åström as its new chairman.
The chairman of the meeting, or a substitute duly appointed by him, was
authorised to apply for registration of the resolutions passed and to make any
such amendments thereto as may be required by the Danish Commerce and Companies
Agency as a condition for registration or approval.
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 83 92
CEO Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer.
TopoTarget has a broad clinical pipeline but is currently focusing on the
development of belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours
where it can be used in combination with full doses of chemotherapy, and is in
phase III in PTCL. TopoTarget's expertise in translational research is
utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget
is directing its efforts on key cancer targets including HDACi, NAD+, mTOR,
FasLigand and topoisomerase II inhibitors. The company's first marketed product
Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is
marketed by TopoTarget's own sales force in Europe and the US. For more
information, please refer to www.topotarget.com.
